Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer: A Prospective Study
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study is being done to help the investigators determine how accurate the sentinel lymph node biopsy (SLNB) procedure is in identifying residual cancer cells after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Female patients over 18 years of age with biopsy-proven breast cancer
• Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
• Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
• Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
Locations
United States
Florida
BAPTIST ALLIANCE - MCI (Data Collection Only)
RECRUITING
Miami
New Jersey
Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up)
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth
RECRUITING
Middletown
Memorial Sloan Kettering Bergen (Consent only and Follow Up)
RECRUITING
Montvale
New York
Memorial Sloan Kettering Commack
RECRUITING
Commack
Memorial Sloan Kettering Westchester
RECRUITING
Harrison
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Memorial Sloan Kettering Nassau (Consent only and Follow Up)
RECRUITING
Uniondale
Contact Information
Primary
Andrea Barrio, MD
barrioa@mskcc.org
646-888-5117
Backup
Monica Morrow, MD
646-888-5350
Time Frame
Start Date: 2017-08-17
Estimated Completion Date: 2026-08-30
Participants
Target number of participants: 170
Treatments
Experimental: Sentinel Lymph Node Biopsy (SLNB)
The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center